Expression of the bacterial gene for cytosine deaminase (CD; EC 3.5.4.1) in mammalian cells was evaluated as a negative selection system or suicide vector for potential use in gene transfer studies and therapies. Mammalian cells, unlike certain bacteria and fungi, do not contain the enzyme CD and do not ordinarily metabolize cytosine to uracil. Nor do they metabolize the innocuous compound 5-fluorocytosine to the highly toxic compound 5-fluorouracil. The Escherichia coli CD gene underwent PCR oligonucleotide-directed mutagenesis to enhance its expression in a eukaryotic system and it was then cloned into an expression vector, pLXSN, that also contains a neomycin-resistance gene. Murine fibroblast lines were transfected with the plasmid and subjected to brief selection in the neomycin analogue G418. Lysates from these cell populations exhibited significant CD activity detected by conversion of radiolabeled cytosine to uracil. In clonogenic assays transfected cells expressing CD were selectively killed by incubation in 5-fluorocytosine, whereas control cell lines were not. Doseresponse studies evaluating [3Hlthymidine incorporation or cloning efficiency demonstrated profound inhibition at and above 65
showed that CD-positive cells could be eliminated without bystander killing of other cells. Retrovirus-mediated CD gene transfer into various tissues was also demonstrated. Thus CD, with its ability to produce the toxic antimetabolite 5-fluorouracil from 5-fluorocytosine, may be useful as a negative selection system for studies and treatments employing gene transfer techniques.
The introduction of genes that confer a phenotype of resistance or sensitivity to various pharmacologic agents and thus allow positive or negative selection of cells has become a critically important technique in studies of molecular genetics and cell biology. Now as human gene therapies are developed applications of negative selection systems may be needed. Such applications could include the use of inserted genes to provide a "suicide" or "fail-safe" trait that would permit the destruction of gene-modified cells if their behavior became harmful to the host.
The enzyme cytosine deaminase (CD; EC 3.5.4.1) catalyzes the deamination of cytosine to uracil (1, 2) . Mammalian cells do not ordinarily produce this enzyme, whereas many bacteria and fungi do. Microorganisms that express the CD gene convert 5-fluorocytosine (5-FCyt) to 5-fluorouracil (5-FUra), a highly toxic metabolite that is lethal to the cell (3) . Since mammalian cells do not express significant amounts of CD they do not deaminate 5-FCyt (4, 5) . This compound is nontoxic to them at concentrations that result in strong antimicrobial activity (6) . However, 5-FUra has potent cytotoxic effects on mammalian cells and is widely used as a cancer chemotherapeutic agent. It is metabolized to 5-fluorouridine 5'-triphosphate and 5-fluoro-2'-deoxyuridine 5'-monophosphate, inhibiting both RNA and DNA synthesis and resulting in cell death (7, 8 (3') (10) . The neomycin phosphotransferase gene was used as a dominant positive selectable marker conferring resistance to the neomycin analogue G418 (11) . pMK116 was digested with the restriction enzymes HincII and BamHI. pLXSN was digested with Hpa I and BamHI. The 1.6-kb fragment from pMK116 and the 5.7-kb fragment from pLXSN were separated and isolated by electrophoresis in a low-melting-point agarose. The fragments were then ligated with T4 ligase, and plasmid preparations were produced employing standard techniques (12, 13) . pCD1 represented the insertion of the unmodified bacterial CD sequence into pLXSN.
Oligonucleotide-directed mutagenesis of pCD1 was conducted in the following way. Oligonucleotides were synthesized on an Applied Biosystems 381A DNA synthesizer and purified by polyacrylamide gel electrophoresis (13) . Oligonucleotides 5'-TGACGCGAATTCAGGCTAGCAAT-GTCG-3' (corresponding to the 5' end of the CD sequence in pCD1 but changing the start codon from GTG to ATG and inserting an EcoRI restriction site immediately upstream of the start codon) and 5'-CACACATTCCACAGCGGATCC-3' (identical antisense to the 3' region flanking the gene in pCD1) were used as primers and pCD1 was used as template in a Abbreviations: CD, cytosine deaminase; 5-FCyt, 5-fluorocytosine; 5-FUra, 5-fluorouracil; LTR, long terminal repeat.
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PCR using a Perkin-Elmer/Cetus DNA thermal cycler. The resulting 1.6-kb fragment representing the modified CD gene and pLXSN were digested with EcoRI and BamHI, electrophoretically isolated, and ligated. The resulting plasmid with the altered CD sequence is called pCD2. The 5' region of the gene was sequenced by the dideoxynucleotide chaintermination method to verify the desired changes in sequence (13) . Southern blots using the same probe were also performed on Sac I digests of 10-,ug samples of purified genomic DNA from cell lines and a 32P-labeled probe corresponding to the 1.6-kb CD gene found between the EcoRI and BamHI sites in pCD2 (13) . As a positive control, 10 pAg of 3T3 DNA was combined with 30 pg of pCD2 representing five copies of the CD gene per cell.
Cellular Techniques. Cell culture. Cells were grown in D10 medium [complete medium based on Dulbecco's modified minimal essential medium (DMEM)-i.e., DMEM supplemented with 10% (vol/vol) heat-inactivated fetal calf serum, 2 mM glutamine, 50 units of penicillin per ml, and 50 pug of streptomycin per ml] and incubated at 37TC in 5% CO2 in air.
NIH 3T3 cells and PA317 cells are mouse fibroblast cell lines that have been described (14) . 207-10 is a methylcholanthrene-induced murine sarcoma line and 38-2 is a dimethylhydrazine-induced colon adenocarcinoma line (both courtesy of S. A. Rosenberg, National Cancer Institute). PA317 has been derived from NIH 3T3 cells and contains a stably integrated replication-incompetent retroviral genome; it functions as a retroviral packaging line when transfected with plasmids containing a retrovirus-like sequence containing an intact packaging sequence (4i). Plasmids pLXSN, pCD1, and pCD2 contain retroviral LTRs and an intact packaging sequence. Cells were transfected with purified plasmid DNA using a standard calcium phosphate precipitation method (13) . The procedure for viral transduction has been described (15) . Cells were exposed to supernatant from packaging lines and 5 ,g of protamine per ml for 24 hr and then grown in D10 medium. Seventy-two hours after plasmid transfection or 48 hr after retroviral transduction, 1 mg of G418 per ml was added to the medium and cells were grown under these selection conditions for 7 days. Thereafter the cells were maintained in D10 medium only.
Clonogenic assay. Cells were diluted to 104 per ml, and 0.1 ml was placed into 4-cm (diameter) flat-bottomed wells of a six-well Costar tissue culture dish along with 5 ml of medium with 5-FCyt (United States Biochemical) and/or G418 (GIBCO) at concentrations described in the text and tables. They were incubated for 5 days, the wells were stained with Geimsa, and colonies of >25 cells were counted under 40x magnification.
Proliferation assay. Cells (103) were placed in flatbottomed wells ofa 96-well plate containing 0.2 ml of medium with additives as described in the tables and text. At the times indicated the wells were pulsed with 25 ,ul of [3H]thymidine with an activity of 0.5 ,Ci/25 IlI (1 Ci = 37 GBq). They were harvested 4 hr later with an automated cell harvester and assayed in a scintillation spectrometer. Twelve replicates of each condition were performed. These and the clonogenic assay data were analyzed by t test (16) .
Enzyme assay. An in vitro assay for CD was performed using a modification of previously described methods (2 G418 should survive in 5-FCyt and the relative cloning efficiency should drop to near zero. Table 2 demonstrates this for 3T3-CD, PA-CD-A, and PA-CD-B. Colony counts in G418 were generally greater than two-thirds of those in control medium containing no additives, indicating considerable enrichment of the population with cells that had incorporated plasmid. For cells treated with 5-FCyt alone the relative colony counts were 3-15% of control counts, indicating that the vast majority of the transfected cells were sensitive to 5-FCyt whereas control cells were not. In medium containing 5-FCyt and G418, almost no colonies of the CD-expressing lines were found. Fig. 2 summarizes the dose-response relationship between 5-FCyt concentration and inhibition of cell line PA-CD-A in clonogenic and proliferation assays. In line PA-CD-A, 5-FCyt profoundly inhibited [3H]thymidine incorporation and colony counts over a concentration range of 62-500 ug/ml; below that range the effects were diminished somewhat but were still significant. Table 3 demonstrates the selectivity of 5-FCyt toxicity in mixed cell populations. Equal numbers of PA-CD-A cells (which contain the CD gene) and PA317 cells (which do not) were mixed in clonogenic assays. If the 5-FCyt toxicity were restricted to cells containing the CD gene, one would expect approximately one-half the cells to be eliminated from the mixed population, whereas nearly all of the cells in a pure PA-CD-A population and none of the cells in a pure PA317 population would be affected by 5-FCyt. However, if there were significant "bystander killing" by release of CD and/or 5-FUra into the medium, one would expect PA-CD-A and Cells (103) were inoculated into tissue culture plates containing medium with the designated additives. After 5 days the plates were stained and colonies were counted. Triplicates of each condition were performed in each experiment. ND, not done. *G418 was used at a concentration of 1 mg/ml except for cell lines 38-2, 38CD, 207-10, and 207CD, where it was 0.3 mg/ml. 5-FCyt was used at a concentration of 0.5 mg/ml except for cell lines 38-2, 38CD, 207-10, and 207CD, where it was 0.125 mg/ml. The ability to render cells selectively susceptible to the toxic effects of 5-FCyt is important for several reasons. (i) It provides a tool potentially useful in basic research as it gives a convenient way to selectively eliminate subpopulations of cells in vitro for studying temporal relationships in interactions between cell types. Similarly, it could be used in vivo in studies of development; certain tissues could be engineered to contain the gene and then selectively eliminated at certain points in development, an approach that has already been used with the aid of the herpes thymidine kinase gene (18) . It could also be used in studies of homologous recombination (19, 20) as an easily assayed target in "knock-out" experiments-i.e., successful homologous recombination in the region of the CD gene could be recognized as loss of sensitivity to 5-FCyt. (ii) The gene could be used in gene transfer therapies as a "suicide vector." Such a vector could contain a desired therapeutic gene and also the CD gene, allowing elimination with 5-FCyt of cells containing the vector. Such a maneuver would be useful for purposes of safety and for regulation of therapeutic gene doses. Employment of this CD system would allow some measure of negative control over the effects of gene expression in the host by allowing one to eliminate or reduce in size the population of genetically engineered cells in the host. This could be especially useful if one wanted to limit the time the host was exposed to the gene product. Similarly, if the therapeutic gene were overexpressed and/or were producing undesired and unforeseen effects (e.g., unwanted metabolic effects or neoplastic transformation of the altered tissues) one could selectively eliminate the tissues with an agent that would not be harmful to the host. The herpes thymidine kinase gene could also be used in this manner as a suicide vector since it confers sensitivity to the antiviral agents ganciclovir and acyclovir (18, 21) . However, these drugs are commonly used in the treatment of viral infections in patients with immunodeficiencies and cancer, the very patients who may benefit from new gene transfer therapies. In this situation, necessary treatment of the viral infection could destroy the genetically altered therapeutic cells. The CD system would provide a superior alternative as 5-FCyt is not often used clinically and many alternative antifungal agents are available for treatment of infections. Alternatively, the CD system may be used to complement thymidine kinase as a suicide vector, providing cells with two unique pathways through which they could be controlled. This may be useful as genetically altered cells can, through various processes, cease to express an alien gene; should a cell lose sensitivity to one it may retain sensitivity to another. (iii) The system may be of use in the development of live vaccines by providing a method for producing "attenuated" or controllable pathogens as immunogens.
